Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224513 | 1.00 | L3MBTL1 (0.56) | L3MBTL1FFAR1FFAR4KDM4EMEN1 | |
| SCHEMBL19959433 | 0.95 | L3MBTL1 (0.51) | L3MBTL1FFAR1FFAR4KDM4EMEN1 | |
| SCHEMBL1822418 | 0.91 | L3MBTL1 (0.67) | L3MBTL1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL17732030 | 0.87 | KDM4E (0.52) | L3MBTL1FFAR1FFAR4KDM4EMEN1 | |
| SCHEMBL5638782 | 0.85 | PKM (0.56) | L3MBTL1FFAR1RECQL | |
| SCHEMBL12223524 | 0.85 | PKM (0.56) | L3MBTL1FFAR1RECQL | |
| SCHEMBL1822003 | 0.85 | FFAR1 (0.58) | L3MBTL1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL12223537 | 0.84 | L3MBTL1 (0.80) | L3MBTL1FFAR4MEN1KMT2APLA2G4B | |
| SCHEMBL21077542 | 0.84 | L3MBTL1 (0.54) | L3MBTL1FFAR1PLA2G4BMMP2LMNA | |
| SCHEMBL12461806 | 0.84 | L3MBTL1 (0.80) | L3MBTL1FFAR4MEN1KMT2APLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11874278-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-11874278-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-20230251264-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230251264-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-3981819-A2 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | Sirigen II Limited (GB) | 2022-04-13 | — | — | EP | disclosed |
| US-10570250-B2 | Dibenzosilole monomers and polymers and methods for their preparation and use | Life Technologies Corporation (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180355098-A1 | DIBENZOSILOLE MONOMERS AND POLYMERS AND METHODS FOR THEIR PREPARATION AND USE | Life Technologies Corporation | 2018-12-13 | — | — | US | disclosed |
| US-10087280-B2 | Dibenzosilole monomers and polymers and methods for their preparation and use | Life Technologies Corporation (US) | 2018-10-02 | — | — | US | disclosed |
| US-20160025735-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-9139869-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139869-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140206557-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8575303-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8455613-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-06-04 | — | — | US | disclosed |
| US-8362193-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362193-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257374-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11874278-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | L3MBTL1 3113/4885FFAR1 4085/4885FFAR4 3786/4885 |
| US-20110257374-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | L3MBTL1 3469/4885FFAR1 3921/4885FFAR4 3676/4885 |
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | L3MBTL1 3469/4885FFAR1 3921/4885FFAR4 3676/4885 |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | L3MBTL1 3469/4885FFAR1 3921/4885FFAR4 3676/4885 |
| US-10570250-B2 | Dibenzosilole monomers and polymers and methods for their preparation and use | DDOST, DDT, DAD1 | L3MBTL1 1332/4885FFAR1 4202/4885FFAR4 4286/4885 |
| US-20180355098-A1 | DIBENZOSILOLE MONOMERS AND POLYMERS AND METHODS FOR THEIR PREPARATION AND USE | DDOST, DDT, DAD1 | L3MBTL1 1332/4885FFAR1 4202/4885FFAR4 4286/4885 |
| US-20230251264-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | L3MBTL1 3469/4885FFAR1 3921/4885FFAR4 3676/4885 |
| US-10087280-B2 | Dibenzosilole monomers and polymers and methods for their preparation and use | DDOST, DDT, DAD1 | L3MBTL1 1332/4885FFAR1 4202/4885FFAR4 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.